Real-world outcomes and corticosteroid sparing with mepolizumab for EGPA or HES
{{output}}
Background: Eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) are rare systemic inflammatory diseases with overlapping features. Mepolizumab, a humanized mAb targeting IL-5, has been approv... ...
